Non-Small Cell Lung Cancer (NSCLC) Treatment Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

By Drug Class (Angiogenesis Inhibitors, Epidermal Growth Factor Receptor Blockers, Kinase Inhibitors, Microtubule Stabilizers, Folate Antimetabolites, and PD-1/ PD-L1 Inhibitors), By Application (Large Cell (Undifferentiated) Carcinoma, Squamous Cell (Epidermoid) Carcinoma, Adenocarcinoma, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global non-small cell lung cancer (NSCLC) treatment market was valued at US$ XX Mn in 2021 and is expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2022 to 2026. Lung cancer usually starts when cells of the lung become abnormal and begin to grow out of control. With the uncontrolled growth of the cancer cells, forms the tumor which tend to spread to the other parts of the body. There are two types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), whereas 10% to 15% are small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is a cell lining air passage, characterized by abnormal cell growth in lung tissue. Depending on the stage of the cancer, there are various treatment options that are available, which include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Key developments in Non-Small Cell Lung Cancer (NSCLC) Treatment Market In February 2018, AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small-cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).


Non-Small Cell Lung Cancer (NSCLC) Treatment Market

MARKET SUMMARY
-
% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– %
  • Largest Market– North America
  • Fastest Growing Market– Europe

Non-Small Cell Lung Cancer (NSCLC) Treatment Marke

  • Non-Small Cell Lung Cancer (NSCLC) Treatment Market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, application, and distribution channel, and region.
  • Non-Small Cell Lung Cancer (NSCLC) Treatment Marketgives comprehensive outlook across the region with special emphasis on key Regional such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Market Key Players
  • Bristol-Myers Squibb (U.S)
  • AstraZeneca plc (U.K)
  • Celgene Corporation (U.S)
  • Boehringer Ingelheim (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S)
Drivers And Restraints

Non-Small Cell Lung Cancer (NSCLC) Treatment Market

Increase in the prevalence of lung cancer is majorly driving the non-small cell lung cancer (NSCLC) treatment market. The growing awareness about the lung cancer diagnosis, treatment and the support from the government organizations expected to enhance the growth of the non-small cell lung cancer (NSCLC) treatment market. The adoption of the unhealthy lifestyle is also adding fuel for to the growth of the market. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012 and according to American Society of cancer, non-small cell lung cancer accounts for ~85% to 90% of overall lung cancer cases. Owing to the larger patient pool, the non-small cell lung cancer (NSCLC) treatment market is expected to exhibit growth over the forecast period. However, the limited treatment options, and the availability of the generic drugs are likely to hinder the growth of the non-small cell lung cancer (NSCLC) treatment market.


North-America got significant share

Non-Small Cell Lung Cancer (NSCLC) Treatment Market

Geographically, global non-small cell lung cancer (NSCLC) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North Americanon-small cell lung cancer (NSCLC) treatment market growth is driven by launch of novel drugs and adoption of novel treatment options in the region. The rise in the patient pool is also adding fuel for the growth of the market in the region. Followed by North America are the regions of Europe and Asia Pacific. The growing penetration of the manufacturers in order to expand geographically in emerging markets expected to drive the growth of the market in these regions.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report covers exhaustive regional information, that includes North America (The USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Venezuela, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market and forecast.
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
Segmentation

Non-Small Cell Lung Cancer (NSCLC) Treatment Market


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Bristol-Myers Squibb (U.S)
  • AstraZeneca plc (U.K)
  • Celgene Corporation (U.S)
  • Boehringer Ingelheim (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S)
  • Eli Lilly and Company (U.S)
  • Roche(Switzerland)
  • Merck & Co.(U.S)
  • Agennix AG (Germany)

Description

The global non-small cell lung cancer (NSCLC) treatment market was valued at US$ XX Mn in 2021 and is expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2022 to 2026. Lung cancer usually starts when cells of the lung become abnormal and begin to grow out of control. With the uncontrolled growth of the cancer cells, forms the tumor which tend to spread to the other parts of the body. There are two types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), whereas 10% to 15% are small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is a cell lining air passage, characterized by abnormal cell growth in lung tissue. Depending on the stage of the cancer, there are various treatment options that are available, which include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Key developments in Non-Small Cell Lung Cancer (NSCLC) Treatment Market In February 2018, AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small-cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX